The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2.
COVID-19
booster
evolution
non-pharmaceutical interventions
vaccination
Journal
Journal of the Royal Society, Interface
ISSN: 1742-5662
Titre abrégé: J R Soc Interface
Pays: England
ID NLM: 101217269
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.
Identifiants
pubmed: 36067790
doi: 10.1098/rsif.2022.0477
pmc: PMC9448498
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
20220477Subventions
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Références
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
Lancet Respir Med. 2022 Feb;10(2):e17
pubmed: 34929158
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138
pubmed: 35611346
Nat Med. 2022 Jun 8;:
pubmed: 35675841
Science. 2022 Mar 11;375(6585):1151-1154
pubmed: 35084937
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
N Engl J Med. 1996 Oct 3;335(14):1022-8
pubmed: 8793926